This site contains promotional information intended only for healthcare professionals resident in Great Britain.
XELJANZ is approved in the UK for active pJIA and jPsA1
|Open-label phase||Double-blind phase|
|XELJANZ* (n=225)||XELJANZ* (n=88)||Placebo (n=85)|
|Number of patients with AEs, n (%)||153 (68.0)||68 (77.3)||63 (74.1)|
|Number of patients with serious AEs, n (%)||7 (3.1)||1 (1.1)||2 (2.4)|
|Number of patients discontinuing due to AEs, n (%)||26 (11.6)||16 (18.2)§||29 (34.1)|
Adapted from Ruperto et al, 2021.2
*XELJANZ 5 mg BID or equivalent weight based lower dose in patients <40 kg.1
§One SAE of pilonidal cyst repair was coded to surgical procedures instead of infections, and was inadvertently not identified as a serious infection. Following adjudication, the serious AE did not meet opportunistic infection criteria. 2
PLEASE SEE XELJANZ SUMMARY OF PRODUCT CHARACTERISTICS FOR FULL INFORMATION
Please click here for an overview of the safety profile of XELJANZ across all licensed indications.
AE, adverse event; ATE, arterial thromboembolism; BID, twice daily; DVT, deep vein thrombosis; ERA, enthesitis-related arthritis; GI, gastrointestinal; ILD, interstitial lung disease; MACE, major adverse cardiovascular event; NMSC, nonmelanoma skin cancer; pcJIA, polyarticular course juvenile idiopathic arthritis; PE, pulmonary embolism; jPsA, juvenile psoriatic arthritis; SAE, serious adverse event; UTI, urinary tract infection.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard or search
for MHRA Yellow Card in Google Play or Apple App Store
Adverse events should also be reported to Pfizer Medical Information on 01304 616161
To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.
This site is intended only for healthcare professionals resident in the United Kingdom. If you are a member of the public wishing to access information on a specific medicine, please visit www.medicines.org.uk/emc
This website is brought to you by Pfizer Limited, a company registered in England
and Wales under No. 526209 with its registered office at Ramsgate Road, Sandwich, Kent, CT13 9NJ
Copyright © 2021 Pfizer Limited. All rights reserved.
VAT registration number GB201048427
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-3863. November 2021
OK, We will need you to sign in before we can determine if you are aligned with a Pﬁzer promotional colleague.
If you have already registered with pfizerpro.co.uk and select ‘yes’, you will be directed to the sign-in page where you will be required to enter your username and password.
Would you like to register or sign in now?